Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06666439 · ClinicalTrials.gov registry record

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

A clinical trial of Metastatic Invasive Lobular Carcinoma (mILC), sponsored by Julia Foldi.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT06666439: Recruiting study of Metastatic Invasive Lobular Carcinoma (mILC), sponsored by Julia Foldi.

NCT06666439 is a study of Metastatic Invasive Lobular Carcinoma (mILC) that is actively recruiting participants, run by Julia Foldi. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06666439, a study of Metastatic Invasive Lobular Carcinoma (mILC), is actively recruiting participants, sponsored by Julia Foldi.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC). Response assessment using ctDNA analysis could not only aid in de-escalation but also escalation strategies.

Primary Outcome

Change in circulating tumor DNA (ctDNA) is measured by MTM/ml in patients receiving first line endocrine therapy (an aromatase inhibitor or fulvestrant) for metastatic lobular breast cancer.

Interventions

  • DIAGNOSTIC_TEST circulating tumor DNA (ctDNA)

Study Locations (1)

Pennsylvania

  • Magee Women's Hospital of UPMC - Pittsburgh

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-12-12
Est. Completion 2029-10-31
Julia Foldi

1 total trials

What NCT06666439 shows while recruiting

NCT06666439 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.

The record links to 1 condition, with Metastatic Invasive Lobular Carcinoma (mILC) appearing as the primary indexed condition, and to 1 intervention - of which circulating tumor DNA (ctDNA) is the first listed.

NCT06666439 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06666439 about?

NCT06666439 is a clinical study titled "Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer". The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC). Response assessment using ctDNA analysis could not only aid in de-escalation but also escalation strategies.

What is the current status of trial NCT06666439?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2024-12-12. Estimated completion is 2029-10-31.

What conditions does trial NCT06666439 study?

This clinical trial studies the following conditions: Metastatic Invasive Lobular Carcinoma (mILC).

What interventions are being tested in trial NCT06666439?

The interventions under investigation include: circulating tumor DNA (ctDNA) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06666439?

This trial is sponsored by Julia Foldi, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06666439 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06666439, the US trial registry maintained by the National Library of Medicine. NCT06666439 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.